300970.SHE Jiangsu Hualv Biological Technology Co.Ltd.
- Market cap
- CNY 1.87B
- P/E
- 25.4x
- P/B
- 1.18x
- ROE
- -1.6%
- Dividend yield
- 0.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300970.SHE undervalued?
Graham number300970.SHE trades 15.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Hualv Biological Technology Co.Ltd. fundamental analysis
No fundamental analysis for Jiangsu Hualv Biological Technology Co.Ltd. yet.
Jiangsu Hualv Biological Technology Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Hualv Biological Technology Co.Ltd.
Jiangsu Chinagreen Biological Technology Group Co.,Ltd. engages in the research, development, factory cultivation, and sale of edible fungi in China. It offers Flammulina velutipes; Pleurotus eryngii, including white jade mushroom and oyster mushroom; and Maitake mushrooms. The company was founded in 2010 and is headquartered in Suqian, China.
Full company profileJiangsu Hualv Biological Technology Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Hualv Biological Technology Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 575M | 609M | 578M | 752M | 996M | 1.03B | 1.29B | 1.33B |
| Gross Profit | 158M | 166M | 38.5M | 123M | 135M | 61.5M | 208M | 106M |
| Operating Income | 128M | 134M | 5.50M | 72.7M | 48.5M | -20.9M | 134M | 5.11M |
| EBITDA | 232M | 222M | 105M | 182M | 169M | 135M | 335M | 11.0M |
| Net Income | 121M | 133M | 15.5M | 78.3M | 30.3M | -47.6M | 110M | -25.3M |
| EPS | 1.38 | 1.51 | 0.13 | 0.52 | 0.20 | -0.30 | 0.69 | -0.16 |
| Balance Sheet | ||||||||
| Total Assets | 1.02B | 1.16B | 1.88B | 1.98B | 2.12B | 2.31B | 2.47B | 2.53B |
| Total Liabilities | 281M | 314M | 439M | 458M | 551M | 786M | 797M | 903M |
| Shareholders' Equity | 737M | 848M | 1.43B | 1.51B | 1.55B | 1.49B | 1.64B | 1.59B |
| Cash & Short-term Investments | 130M | 192M | 411M | 432M | 410M | 361M | 590M | 550M |
| Cash Flow | ||||||||
| Operating Cash Flow | 214M | 199M | 83.1M | 180M | 167M | 138M | 345M | - |
| Capital Expenditure | 98.5M | 191M | 204M | 408M | 224M | 268M | 123M | 112M |
| Free Cash Flow | 115M | 8.13M | -121M | -228M | -57.5M | -130M | 222M | 127M |
| Ratios | ||||||||
| ROE | 16.4% | 15.6% | 1.1% | 5.2% | 2.0% | -3.2% | 6.7% | -1.6% |
| ROA | 11.9% | 11.4% | 0.8% | 4.0% | 1.4% | -2.1% | 4.5% | -1.0% |
| Net Profit Margin | 21.0% | 21.7% | 2.7% | 10.4% | 3.0% | -4.6% | 8.5% | -1.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jiangsu Hualv Biological Technology Co.Ltd. dividends
- Dividend yield
- 0.62%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 10.5%
- Ex-dividend date
- Jun 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 11.5M | 0.07 | 10.5% |
| 2024 | CNY 33.6M | 0.21 | - |
| 2023 | CNY 35.6M | 0.23 | 117.1% |
| 2022 | CNY 2.69M | 0.02 | 3.4% |
| 2021 | CNY 35.8M | 0.31 | 230.7% |
| 2020 | CNY 28.8M | 0.33 | 21.7% |
| 2019 | CNY 27.7M | 0.32 | 23.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 9, 2026.
Who owns Jiangsu Hualv Biological Technology Co.Ltd.
- Insiders 44.02%
- Institutions 5.07%
- Public & others 50.91%
- Shares outstanding 160M
- Free float 97.5M
Jiangsu Hualv Biological Technology Co.Ltd. company profile
- Company name
- Jiangsu Hualv Biological Technology Co.Ltd.
- Ticker
- 300970.SHE
- ISIN
- CNE100004KF5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 2,388
- Fiscal year end
- December
- Address
- No. 88, Ludu Avenue, Suqian, China, 223700
- Phone
- 86 527 8530 2330
- Website
- chinagreenbio.com
About Jiangsu Hualv Biological Technology Co.Ltd.
Jiangsu Chinagreen Biological Technology Group Co.,Ltd. engages in the research, development, factory cultivation, and sale of edible fungi in China. It offers Flammulina velutipes; Pleurotus eryngii, including white jade mushroom and oyster mushroom; and Maitake mushrooms. The company was founded in 2010 and is headquartered in Suqian, China.
Jiangsu Hualv Biological Technology Co.Ltd. management
5- Mr. Yangchao YuChairman & GM · born 1971
- Mr. Qian TaoCFO, Secretary & Director · born 1986
- Mr. Jianfeng JiangDeputy GM & Director · born 1965
- Mr. Feng ZhanDeputy GM & Director · born 1985
- Ms. Fen LiAccounting Supervisor · born 1981